Focusing sharply on its core business resulted in a 68 per cent compound annual growth rate (CAGR), reducing adjusted negative EBITDA from Rs 162 crore to Rs 17 crore
Read More
For the annual performance in FY24, HCG's revenue was Rs 19,121 million
Read More
For the fiscal year 2023-24, Indegene witnessed a 12.3 per cent year-on-year (YoY) growth in revenue, reaching Rs 25,896 million
Read More
On an yearly basis, gross profit for FY24 was Rs16,291 million, up 22 per cent from Rs 13,328 million in FY23
Read More
In Q4 FY24, JB Pharma recorded a revenue of Rs 862 crores, marking a 13 per cent increase from Rs 762 crores in Q4 FY23
Read More
